Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 5/20 | 0.49 |
| ▸ | CDK8 | P49336 | 5/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.35 |
| ▸ | CDK2 | P24941 | 6/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.35 |
| ▸ | PLK1 | P53350 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039119 | 0.92 | CCNC (0.61) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7041432 | 0.88 | CCNC (0.46) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7249998 | 0.80 | CCNC (0.48) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7065565 | 0.79 | CCNC (0.61) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7246869 | 0.79 | DRD4 (0.68) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7063926 | 0.78 | CCNC (0.60) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7249355 | 0.78 | DRD4 (0.45) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7247103 | 0.76 | CCNC (0.54) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7246668 | 0.76 | CCNC (0.54) | CCNCCDK8CDK19DRD2DRD4 | |
| SCHEMBL7246892 | 0.76 | CCNC (0.41) | CCNCCDK8CDK19DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1293197-A1 | PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | PHOSPHO1, PLTP, PTDSS2 | CCNC 3385/4885CDK8 2673/4885CDK19 3344/4885 |
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | CCNC 2012/4885CDK8 3614/4885CDK19 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.